Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

Austria
Belgium
Portugal
The Netherlands
Canada
PERescue
Translating Peroxisome Biogenesis Disorders: Identifying Pharmacological Therapies and Clinical Trial Endpoints

Project Coordinator

The Research Institute of the McGill University health Center
Montreal
Canada

Partners

Pedro Brites Instituto de Biologia Molecular e Celular – IBMC Porto, Portugal
Paul Van Veldhoven KU Leuven, Campus Leuven, Belgium, Flanders
Johannes Berger Medical University of Vienna Vienna, Austria
Bwee Poll-The Academic Medical Center at the University of Amsterdam Amsterdam, The Netherlands
Hans Waterham Academic Medical Center at the University of Amsterdam Amsterdam, The Netherlands

Peroxisome biogenesis disorders (PBD) are rare autosomal recessive disorders caused by defects in any one of 14 PEX genes whose protein products are required for peroxisome assembly. Defective peroxisome assembly results in multiple peroxisomal enzyme deficiencies and multi-organ failure over life span. The majority of patients have PEX gene defects that retain residual PEX protein functions, and thus should be amenable to drug therapies that can enhance residual function or mitigate downstream metabolic defects. Importantly, there is a window to intervene in PBD and prevent or ameliorate disease progression. Currently there is no treatment for PBD. In pilot studies, we identified chaperone drugs that can recover peroxisome functions in patient cell lines. We have also identified drugs that increase peroxisome numbers and correct affected downstream signaling pathways. We have shown that plasmalogens, a critical missing compound, can be replaced in somatic tissues by supplementation. Thus, we hypothesize that pharmacological therapies, based on manipulating the affected molecular and metabolic pathways, have valid potential to benefit PBD patients. In this project we will utilize our complementary resources and expertise to focus on identifying drug therapies that can recover peroxisome functions in our model systems. With our clinical expertise, we will mine our patient databases to determine rational endpoints for human trials. The completion of this project will lay solid groundwork for industry to optimize these therapeutic approaches for future clinical trials.

E-Rare 2012 - Created by Toussaint Biger